Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages

  Piroth, Marc D ^a,b   Pinkawa, Michael ^a,b   Holy, Richard ^a,b   Stoffels, Gabriele ^b   Demirel, Cengiz ^a   Attieh, Charbel ^a   Kaiser, Hans J ^a   Langen, Karl J ^b   Eble, Michael J ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

O (2 FLUOROETHYL) LEVO TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; O (2 ((18)F)FLUOROETHYL) L TYROSINE; O-(2-((18)F)FLUOROETHYL)-L-TYROSINE; TYROSINE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; FEASIBILITY STUDY; FEMALE; GEOMETRY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTEGRATED BOOST INTENSITY MODULATED RADIATION THERAPY; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MALE; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; THREE DIMENSIONAL CONVENTIONAL RADIATION THERAPY; TREATMENT PLANNING; BRAIN TUMOR; COMPUTER ASSISTED RADIOTHERAPY; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TYROSINE;

EID: 71549148685     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-57     Document Type: Article

References (62)

1. Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996. 10.1056/NEJMoa043330, 15758009.
2. Stupp R, Hegi ME, Mason WP, Bent MJ, Taphoorn MJ, Janzer RC. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-466. 10.1016/S1470-2045(09)70025-7, 19269895.
3. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991, 64(4):769-774. 1977696, 1654987.
4. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979, 5(10):1725-1731.
5. Taghian A, Ramsay J, Allalunis-Turner J, Budach W, Gioioso D, Pardo F. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1993, 25(2):243-249.
6. Taghian A, DuBois W, Budach W, Baumann M, Freeman J, Suit H. In vivo radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1995, 32(1):99-104.
7. Taghian A, Suit H, Baumann M. In vitro and in vivo radiation sensitivity of glioblastoma multiforme: correction. Int J Radiat Oncol Biol Phys 1996, 35(5):1124-1125.
8. Taghian A. In vitro and in vivo radiation sensitivity of glioblastoma multiforme: correction. Int J Radiat Oncol Biol Phys 1998, 42(2):464.
9. Loeffler JS, Alexander E, Shea WM, Wen PY, Fine HA, Kooy HM. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992, 10(9):1379-1385.
10. Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Levin AB. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1995, 32(4):931-941.
11. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004, 60(3):853-860.
12. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63(2):511-519.
13. Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009, 73(2):479-485.
14. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M. Cerebral glioma: evaluation with methionine PET. Radiology 1993, 186(1):45-53.
15. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005, 128(Pt 3):678-687. 10.1093/brain/awh399, 15689365.
16. Rachinger W, Goetz C, Popperl G, Gildehaus FJ, Kreth FW, Holtmannspotter M. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005, 57(3):505-511. 10.1227/01.NEU.0000171642.49553.B0, 16145529.
17. Fuss M, Salter BJ, Rassiah P, Cheek D, Cavanaugh SX, Herman TS. Repositioning accuracy of a commercially available double-vacuum whole body immobilization system for stereotactic body radiation therapy. Technol Cancer Res Treat 2004, 3(1):59-67.
18. Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006, 33(3):287-294. 10.1016/j.nucmedbio.2006.01.002, 16631076.
19. Roesch P, Netsch T, McNutt T, Shoenbill J, Roost P. Syntegra - Automated image registration algorithms. Philips White Paper 2003,
20. Weckesser M, Griessmeier M, Schmidt D, Sonnenberg F, Ziemons K, Kemna L. Iodine-123 alpha-methyl tyrosine single-photon emission tomography of cerebral gliomas: standardised evaluation of tumour uptake and extent. Eur J Nucl Med 1998, 25(2):150-156. 10.1007/s002590050208, 9473263.
21. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004, 31(11):1464-1470. 10.1007/s00259-004-1590-1, 15248032.
22. Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005, 32(4):422-429. 10.1007/s00259-004-1705-8, 15650870.
23. Prescribing, Recording and Reporting Photon Beam Therapy. Journal of the International Commission on Radiation Units and Measurements 1993, Report 50.
24. Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU 50 Report). Journal of the International Commission on Radiation Units and Measurements 1999, Report 62.
25. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21(1):109-122.
26. Tome WA, Meeks SL, Buatti JM, Bova FJ, Friedman WA, Li Z. A high-precision system for conformal intracranial radiotherapy. Int J Radiat Oncol Biol Phys 2000, 47(4):1137-1143.
27. Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg 2000, 3:219-222.
28. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997, 24(1):103-110. 10.1118/1.598063, 9029544.
29. Niemierko A. Radiobiological models of tissue response to radiation in treatment planning systems. Tumori 1998, 84(2):140-143.
30. RaySearch Laboratories AB SS Biological optimization using the equivalent uniform dose (EUD) in Pinnacle3. RaySearch White Paper 2003, WP-EUD rev.1, 0310.
31. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991, 21(1):123-135.
32. Luxton G, Keall PJ, King CR. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD). Phys Med Biol 2008, 53(1):23-36. 10.1088/0031-9155/53/1/002, 18182685.
33. Semenenko VA, Reitz B, Day E, Qi XS, Miften M, Li XA. Evaluation of a commercial biologically based IMRT treatment planning system. Med Phys 2008, 35(12):5851-5860. 10.1118/1.3013556, 19175141.
34. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30(9):907-911.
35. Jansen EP, Dewit LG, van HM, Bartelink H. Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 2000, 56(2):151-156. 10.1016/S0167-8140(00)00216-4, 10927133.
36. Shrieve DC, Alexander E, Black PM, Wen PY, Fine HA, Kooy HM. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999, 90(1):72-77. 10.3171/jns.1999.90.1.0072, 10413158.
37. Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T. High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncol 2005, 6(12):953-960. 10.1016/S1470-2045(05)70395-8, 16321763.
38. Irish WD, Macdonald DR, Cairncross JG. Measuring bias in uncontrolled brain tumor trials--to randomize or not to randomize?. Can J Neurol Sci 1997, 24(4):307-312.
39. Litofsky NS, Bauer AM, Kasper RS, Sullivan CM, Dabbous OH. Image-guided resection of high-grade glioma: patient selection factors and outcome. Neurosurg Focus 2006, 20(4):E16. 10.3171/foc.2006.20.4.10, 16709021.
40. Winger MJ, Macdonald DR, Schold SC, Cairncross JG. Selection bias in clinical trials of anaplastic glioma. Ann Neurol 1989, 26(4):531-534. 10.1002/ana.410260406, 2684003.
41. Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys 2009, 73(3):699-708.
42. Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998, 41(5):1005-1011.
43. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002, 51(2):343-355. 10.1097/00006123-200208000-00009, 12182772.
44. Rickhey M, Koelbl O, Eilles C, Bogner L. A biologically adapted dose-escalation approach, demonstrated for 18F-FET-PET in brain tumors. Strahlenther Onkol 2008, 184(10):536-542. 10.1007/s00066-008-1883-6, 19016044.
45. Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging 2009, 36(2):182-193. 10.1007/s00259-008-0943-6, 18818918.
46. Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M. [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008, 3:44. 10.1186/1748-717X-3-44, 2628662, 19108742.
47. Weltens C, Menten J, Feron M, Bellon E, Demaerel P, Maes F. Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging. Radiother Oncol 2001, 60(1):49-59. 10.1016/S0167-8140(01)00371-1, 11410304.
48. Cozzi L, Fogliata A, Bolsi A, Nicolini G, Bernier J. Three-dimensional conformal vs. intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys 2004, 58(2):617-624.
49. Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003, 57(3):875-890.
50. Selvaraj RN, Beriwal S, Pourarian RJ, Lalonde RJ, Chen A, Mehta K. Clinical implementation of tangential field intensity modulated radiation therapy (IMRT) using sliding window technique and dosimetric comparison with 3D conformal therapy (3DCRT) in breast cancer. Med Dosim 2007, 32(4):299-304. 10.1016/j.meddos.2007.03.001, 17980832.
51. Pinkawa M, Siluschek J, Gagel B, Piroth MD, Demirel C, Asadpour B. Postoperative radiotherapy for prostate cancer: evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy). Strahlenther Onkol 2007, 183(1):23-29. 10.1007/s00066-007-1588-2, 17225942.
52. Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol 2009, 93(2):213-219. 10.1016/j.radonc.2009.07.014, 19717197.
53. Pirzkall A, Carol M, Lohr F, Hoss A, Wannenmacher M, Debus J. Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys 2000, 48(5):1371-1380.
54. Chan MF, Schupak K, Burman C, Chui CS, Ling CC. Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim 2003, 28(4):261-265. 10.1016/j.meddos.2003.08.004, 14684191.
55. Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 2006, 64(3):892-897.
56. MacDonald SM, Ahmad S, Kachris S, Vogds BJ, DeRouen M, Gittleman AE. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. J Appl Clin Med Phys 2007, 8(2):47-60.
57. Hermanto U, Frija EK, Lii MJ, Chang EL, Mahajan A, Woo SY. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain?. Int J Radiat Oncol Biol Phys 2007, 67(4):1135-1144.
58. Thilmann C, Zabel A, Grosser KH, Hoess A, Wannenmacher M, Debus J. Intensity-modulated radiotherapy with an integrated boost to the macroscopic tumor volume in the treatment of high-grade gliomas. Int J Cancer 2001, 96(6):341-349. 10.1002/ijc.1042, 11745504.
59. Chang EL, Akyurek S, Avalos T, Rebueno N, Spicer C, Garcia J. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007, 68(1):144-150.
60. Tome WA, Fowler JF. On cold spots in tumor subvolumes. Med Phys 2002, 29(7):1590-1598. 10.1118/1.1485060, 12148742.
61. Qi XS, Schultz CJ, Li XA. An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor. Int J Radiat Oncol Biol Phys 2006, 64(5):1570-1580.
62. Thieke C, Bortfeld T, Niemierko A, Nill S. From physical dose constraints to equivalent uniform dose constraints in inverse radiotherapy planning. Med Phys 2003, 30(9):2332-2339. 10.1118/1.1598852, 14528955.